IP Library Granted Patent US 9,879,075
Granted Patent B2
US 9,879,075 · App. 14/766,062 · Granted Jan 30, 2018

Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same

Inventors: Yoshio Goshima (Yokohama, JP); Fumio Nakamura (Yokohama, JP); Naoya Yamashita (Yokohama, JP); Hidetaka Seo (Tokyo, JP); Shuichi Hashimoto (Tokyo, JP); Koji Murakami (Tokyo, JP); Naoki Takahashi (Chiba, JP); Yukie Sasakura (Tokyo, JP)
Assignee: Yokohama City University and Chiome Bioscience Inc.
C07K16/18A61K2039/505C07K2317/22C07K2317/24C07K2317/33C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,879,075
App. No.
14/766,062
Granted
Jan 30, 2018
Kind
B2
Abstract

The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome. An anti-Sema 3A antibody comprising CDRs having specific amino acid sequences (SEQ ID NOS: 1-6, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86 and 88-90) enables effective prevention and/or treatment of a disease, in which Sema 3A protein participates, such as a neurodegenerative disease, autoimmune disease, inflammatory disease, cancer, infectious disease, etc. or disseminated intravascular coagulation syndrome and, therefore, remarkably ameliorates symptoms associated with such a disease.

Claims (7)

1. An anti-semaphorin 3A antibody comprising:

a heavy chain CDR1 having an amino acid sequence shown in SEQ ID NO:1, CDR2 having an amino acid sequence shown in SEQ ID NO:2, and CDR3 having an amino acid sequence shown in SEQ ID NO:3; and

a light chain CDR1 having an amino acid sequence shown in SEQ ID NO:4, CDR2 having an amino acid sequence shown in SEQ ID NO:5, and CDR3 having an amino acid sequence shown in SEQ ID NO:6.

2. The anti-semaphorin 3A antibody or antibody fragment thereof according to claim 1 , wherein the antibody or antibody fragment thereof is a chimeric antibody, a humanized antibody or an antibody fragment thereof.

3. A pharmaceutical composition comprising the anti-semaphorin 3A antibody or antibody fragment thereof according to claim 1 .

4. A method for measuring Sema 3A protein, comprising measuring Sema 3A protein in a sample using immunoassay with the anti-Sema 3A antibody or antibody fragment thereof according to claim 1 .

5. A kit for measuring Sema 3A protein, comprising the anti-Sema 3A antibody or antibody fragment thereof according to claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2018
From: SASAKURA, YUKIE
To: YOKOHAMA CITY UNIVERSITY; CHIOME BIOSCIENCE INC.
Reel/Frame 044982/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2017
From: GOSHIMA, YOSHIO; NAKAMURA, FUMIO; YAMASHITA, NAOYA; SEO, HIDETAKA; HASHIMOTO, SHUICHI; MURAKAMI, KOJI; TAKAHASHI, NAOKI
To: YOKOHAMA CITY UNIVERSITY; CHIOME BIOSCIENCE INC.
Reel/Frame 044412/0120 →
Priority Claims (1)
JP 2013-021309 · Feb 6, 2013 · national
Continuity (1)
Related Publication 20150368327A1 · Dec 24, 2015